Invasive pulmonary aspergillosis
IPA · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Invasive aspergillosis is an angioinvasive mould infection mainly affecting neutropenic and other immunocompromised hosts, typically pulmonary. Early voriconazole/isavuconazole and reduction of immunosuppression are crucial; mortality is high.
Red flags
- Massive haemoptysis (vessel erosion)
- Rapidly progressive hypoxia
- Dissemination (cerebral aspergillosis)
- Breakthrough infection on azole prophylaxis (consider resistance)
- Persistent profound neutropenia
Assessment
Differential diagnosis
- Bacterial pneumonia
- Mucormycosis
- Pulmonary embolism/infarct
- Other invasive mould or PCP
- Malignancy/haemorrhage
Investigations
- CT chest (nodules with halo sign, cavitation, air-crescent)
- Serum and bronchoalveolar lavage galactomannan
- BAL fungal culture and microscopy
- Beta-D-glucan (non-specific)
- Aspergillus PCR where available
- Assess net state of immunosuppression / neutrophil count
Management
- Suspect in prolonged neutropenia or heavy immunosuppression with fever/pulmonary signs
- Obtain CT chest early (halo sign is an early clue)
- Send serum galactomannan and arrange bronchoscopy with BAL galactomannan/culture
- Start antifungal therapy promptly in probable/proven disease
- Choose voriconazole or isavuconazole first line
- Reduce immunosuppression and support neutrophil recovery where possible
- Perform therapeutic drug monitoring for voriconazole
- Consider surgery for localised lesions near great vessels or massive haemoptysis
- Monitor response with repeat imaging and galactomannan trend
- Manage drug interactions (azoles are potent CYP inhibitors)
- Continue therapy for a prolonged course guided by response and immune recovery
- Give secondary prophylaxis if immunosuppression continues
Drugs & doses
Voriconazole 6 mg/kg IV every 12 h for 2 doses then 4 mg/kg every 12 h (target trough 1-5.5 mg/L)
Isavuconazole 200 mg (loading every 8 h for 6 doses) then 200 mg once daily
Liposomal amphotericin B 3-5 mg/kg IV daily (alternative/intolerance)
Posaconazole (salvage or where resistance/intolerance) with level monitoring
Disposition
Admit (critical); haematology/ID; consider thoracic surgery for complications.
Complications & pitfalls
- Pulmonary haemorrhage/haemoptysis
- Dissemination to brain and other organs
- Respiratory failure
- Azole toxicity and drug interactions
- High mortality
Exam pearls
- The CT halo sign is an early, time-sensitive diagnostic clue - act on it
- Voriconazole needs therapeutic drug monitoring; levels vary widely
- Distinguish from mucormycosis - voriconazole does not cover mucorales
- Galactomannan from BAL is more sensitive than serum in non-neutropenic patients
- Reversing immunosuppression/neutropenia is as important as antifungals
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.